🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. NNC0487-0111 B 10142, Placebo (NNC0487-0111), NNC0487-0111 B 10143, NNC0487-0111 B 10146, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10141

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  2. NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10142, NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  3. NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  4. NNC0487-0111 B 10146, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10143, NNC0487-0111 B 10144, NNC0487-0111 B 10142, NNC0487-0111 B 10141

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  5. NNC0487-0111 B 10146, Placebo, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10145, NNC0487-0111 B 10144

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. NUBEQA 300 mg film-coated tablets, Placebo to BAY1841788 film-coated tablet 300 mg

    Ningbo Cancer Hospital

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  7. NUC01, Placebo to NUC01

    Dr. Falk Pharma GmbH

    primary sclerosing cholangitis (PSC)

    phase 3 small molecule active

    1 trial

  8. NaCl 0.9%, PREDNISONE ARROW 20 mg, comprimé sécable, METHYLPREDNISOLONE , Placebo de prednisone ARW 20 mg - Hydrogénophosphate de calcium dihydraté (94%) Stéarate de magnésium (1%) Amidon de maïs Lycatab C (5%), Glucose 5%

    Pari Pharma GmbH

    Erythema multiforme (EM) in its severe form managed at the hospital

    phase 3 small molecule active

    1 trial

  9. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis (MS)

    phase 3 small molecule terminated

    1 trial

  10. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity in Participants With Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  11. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Post-Traumatic Stress Disorder

    phase 3 small molecule terminated

    1 trial

  12. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    3 trials

  13. Nabiximols

    Jazz Pharmaceuticals Ireland Limited

    Spasticity With Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  14. Nalfurafine Hydrochloride

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Uremic Pruritus

    phase 3 small molecule active

    1 trial

  15. Nano-crystalline Megestrol Acetate Oral Suspension

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  16. Nanocovax

    Biotech Pharmaceutical Co.,

    SARS-CoV-2 Infection

    phase 3 mab completed

    1 trial

  17. Neuraceq 300 MBq/mL solution for injection

    Fondazione Telethon ETS

    cardiac amyloidosis

    phase 3 small molecule active

    1 trial

  18. Nilemdo 180 mg film-coated tablets, Obicetrapib, Obicetrapib matching placebo, Bempedoic acid matching placebo

    A.Menarini Australia Pty Limited

    Dyslipidemia at High to Very High Cardiovascular Risk

    phase 3 small molecule active

    1 trial

  19. Nilotinib

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  20. Nilotinib (AMN107)

    Novartis Pharmaceuticals

    Gastrointestinal Stromal Tumor (GIST)

    phase 3 small molecule completed

    1 trial

  21. Niraparib - capsule - 100 mg, Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for ABIRATERONE ACETATE, -, Niraparib, PREDNISOLONE , ABIRATERONE , Placebo for Niraparib, Abiraterone acetate - tablet - 250 mg, Placebo for NIRAPARIB / ABIRATERONE ACETATE 50/500 mg FDC, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, Prednison acis 5 mg, Tabletten, Placebo for NIRAPARIB / ABIRATERONE

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  22. Niraparib Placebo Capsules, Niraparib Placebo Tablets, G5W (5% glucose in water), JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Recurrent or primary advanced (Stage III or IV) endometrial cancer

    phase 3 small molecule active

    1 trial

  23. Niraparib Placebo Tablets

    GlaxoSmithKline

    Neoplasms, Breast

    phase 3 small molecule active

    1 trial

  24. Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources